Regulatory & Legal

The revered former U.S. Senator announced his withdrawal from public life following a dementia diagnosis, ending a storied career and sparking reflection.

As thousands celebrate, a massive art installation will project faces asking if they're next for immigration raids, turning a party into a protest.

Starlight U.S. Residential LP finalizes a strategic overhaul and new listing, but a looming loan default on a key property raises critical questions.

Vivakor blames a government shutdown for its dividend delay, but shareholders are left grappling with an unusual asset and a complex CEO-related deal.

With platinum prices soaring, junior miner ValOre Metals is pivoting to development at its unique Brazilian project, signaling a potential closing of its valuation gap.

With 19 locations, Chroma Early Learning Academy's growth addresses childcare gaps and sets new safety and community standards across Metro Atlanta.

Cannabix Technologies lands its first international order for its smart breathalyzer in Australia, a move that validates its tech and reshapes its finances.

With a major funding round, Biobeat aims to replace bulky cuffs with a discreet patch, potentially revolutionizing hypertension care for millions.

Facing a Nasdaq delisting threat, China-based WF International has 180 days to revive its stock after a dramatic collapse since its April IPO.

Hyatt finalizes a $2B asset sale to Tortuga Resorts, advancing its asset-light strategy while navigating hurricane recovery in the Caribbean.

Sidus Space nets nearly $15M in a new offering to scale satellite production and defense tech, sparking investor optimism despite financial pressures.

Investors await Polaris's Q4 results on Jan. 27, seeking clarity on market share gains, tariff impacts, and the future of its Indian Motorcycle brand.

Emmaus Life Sciences outsources its sickle cell drug Endari® in North America to focus on global growth, as NeoImmuneTech gains a key U.S. market foothold.

KORU Medical seeks FDA clearance for its FreedomEDGE® system with a key breast cancer drug, signaling a major shift in cancer care delivery.

Fitch Ratings awards NETSTREIT a BBB- rating, a milestone affirming its conservative strategy and unlocking new avenues for growth and capital efficiency.

As Axos sets to reveal its Q2 results, investors weigh strong growth forecasts against mounting concerns over margin pressure and a shifting economy.

With a new $500 million credit line, Ramaco Resources is doubling down on its unique strategy: growing its coal business while racing to develop a US rare earth mine.

Fresh off a successful IPO, Ceribell is set to showcase its revolutionary AI-powered EEG system, a device already changing outcomes in ICUs nationwide.

A 41-year-old mother's massive heart attack on Valentine's Day sparked a miraculous story of survival, advanced medicine, and profound gratitude.

The biopharma investment giant has now acquired 100% of the royalty stream for Roche's blockbuster SMA drug, a strategic move years in the making.